<DOC>
	<DOCNO>NCT02537990</DOCNO>
	<brief_summary>The purpose study : 1 . To identify quantify health utility quality life experience patient diagnosed MDS predictor . 2 . Measure effect patient related factor like frailty comorbidity quality life overall survival toxicity therapy . 3 . Assess quality life change time predictor . This valuable information may guide therapy , transfusion practice , etc. , MDS chronic , incurable disease often progressive .</brief_summary>
	<brief_title>MDS-CAN : A Prospective National MDS Clinical Database Local Tissue Bank</brief_title>
	<detailed_description>Participants see assess study every 6 ( +/-1 ) month . Follow-up routine clinical care dictate physician . Clinical information relevant MDS diagnosis enter IPSS , IPSS-R , treatment receive response . Transfusion dependence record . Relevant laboratory ferritin , LDH , CBC etc enter q 6 month . Hospitalizations , bleed infection record . Dates cause death document Dates leukaemia transformation document . Patients undergo allogeneic stem cell transplant document date transplant . QOL assess every 6 month : QOL instrument QLQ-C30 , QUALMS , EQ-5D global fatigue scale Disability , frailty , comorbidity physical performance record yearly basis Disability scale Lawton Brody SIADL scale Frailty measure use Rockwood clinical frailty scale The comorbidity elements necessary calculate Charlson comorbidity scale MDS-CI Della Porta et al . recorded Physical performance test grip strength , 10x stand sit test 4 meter walk test Investigators continue enroll new patient throughout study period 6 year , plan ( fund permit ) continue registry indefinitely , late question address . - Monitoring audit data complete every quarter dedicate national registry project manager . - Monthly data check complete compare data enter registry predefined rule range consistency data field registry . - Standard Operating Procedures address registry operation analysis activity , patient recruitment data collection create post electronically database site . - Plan 25 % drop death assume due conversion AML non leukemia death 5 % lose follow loss follow . This purpose address situation variable report miss , unavailable , `` non-reported , '' uninterpreted , consider miss data inconsistency out-of-range . - Participant 's result summarize descriptively whole province . KM survival curve generate compare use log-rank test . Univariate multivariate cox proportional hazard nodel overall survival perform detect significant association baseline covariates time-dependent covariates frailty , comorbidity QOL score use Statistical Analysis Software ( SAS ) PHREG procedure .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>New diagnosis Myelodysplastic syndrome New diagnosis CMML1/CMML2 MDS/MPN New diagnosis low blast AML ( blast 2030 % ) define WHO classification ( Vardiman , 2002 ) Greater 18 year age time diagnosis Able read , write speak English French ( nonEnglish French speaking patient may participate appropriate translation use ) Able consent . Patients whose diagnostic bone marrow exceed 2 year prior sign consent Subjects AML bone marrow blast 31 % time signing consent Prior allogenic cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>